Pure Global AI
NCT05826366Recruiting

Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Specific Use-results Study of IMJUDO Intravenous Infusion 25mg / IMFINZI Intravenous Infusion 120mg,500mg All Patient Investigation in Patients With Unresectable Advanced or Recurrent Non-small Cell Lung Cancer
AstraZenecaClinicalTrials.gov
Verified
Study focus
Disease/Condition
Carcinoma, Non-Small-Cell Lung
Study type
Observational
Sponsor & location
Primary sponsor
AstraZeneca
Location
Aichi,Akita,Aomori,Chiba,Fukuoka,Fukushima,Gifu,Gunma,Hiroshima,Hokkaido,Hyogo,Hyogo,Ibaraki,Iwate,Kanagawa,Kanagawa,Kumamoto,Kyoto,Mie,Miyagi,Nagano,Oita,Osaka,Osaka,Saitama,Shizuoka,Tokyo,Tokyo,Toky, Japan
Timeline & enrollment
Phase
N/A
Start date
Jun 02, 2023
End date
Nov 16, 2025
Enrollment
200 participants
Primary outcome

Incidence of ADRs

Summary

To collect information of safety in patients with unresectable advanced or recurrent
 non-small cell lung cancer who receive combination therapy of IMJUDO, IMFINZI and other
 platinum-based anti-cancer agents under actual use in the postmarketing setting.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05826366
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05826366 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.